Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.459,05-0,70 %

Gold3.323,49+0,01 %

Öl (Brent)68,92-1,70 %

Dow Jones44.652,82+0,45 %

US Tech 10022.829,75-0,13 %

EUR/USD1,17042+0,01 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Aktie

ISIN: US15117N6022 WKN: A3DWEJ SYM: IMNN Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,6500

USD

-7,84 %

-0,0553 USD

Letzter Kurs 10.07.25 NYSE

Imunon Aktie kaufen

Geldkurs

10.07.25

0,6425

USD

100 STK

Briefkurs

10.07.25

0,6500

USD

100 STK

BEI SMARTBROKER+ HANDELN

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Baader Tragding

Neueste Nachrichten

IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period 30.06.25 · globenewswire · Imunon
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 18.06.25 · globenewswire · Imunon
IMUNON Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development 17.06.25 · globenewswire · Imunon
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th 05.06.25 · globenewswire · Imunon
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study 03.06.25 · globenewswire · Imunon
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS 02.06.25 · globenewswire · Imunon
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules 28.05.25 · globenewswire · Imunon
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 27.05.25 · globenewswire · Imunon
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules 24.05.25 · globenewswire · Imunon
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer 23.05.25 · globenewswire · Imunon
IMUNON Announces Withdrawal of Form S-1 Registration Statement 22.05.25 · globenewswire · Imunon
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 15.05.25 · globenewswire · Imunon

1
2
3
…
4

Meistgelesen

30 Tage
12 Monate

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO ... 152 Leser
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing ... 140 Leser
IMUNON Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th ... 124 Leser

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced ... 624 Leser
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules 580 Leser
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on ... 560 Leser
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update 476 Leser
IMUNON to Host R&D Day on September 18th 436 Leser
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian ... 424 Leser
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study ... 312 Leser
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study ... 240 Leser
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian ... 228 Leser
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in ... 204 Leser